WIDEN: A tool for medical image management in multicenter clinical trials
暂无分享,去创建一个
Piergiorgio Cerello | Orazio Schillaci | Anna Cavallo | Umberto Ficola | Alberto Biggi | P. Cerello | O. Schillaci | F. Fallanca | S. Chauvie | A. Biggi | A. Gallamini | M. Gregianin | A. Stancu | A. Cavallo | U. Ficola | U. Guerra | A. Chiaravalloti | Ugo Paolo Guerra | Alexandru Stancu | Agostino Chiaravalloti | Andrea Gallamini | Michele Gregianin | Stéphane Chauvie | Federico Fallanca
[1] Paul G Nagy,et al. Cloud computing in medical imaging. , 2013, Medical physics.
[2] F. d'Amore,et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Gambhir. Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.
[4] J. Radford,et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[5] B. Freidlin,et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M E Phelps,et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] B. Cheson,et al. Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.
[8] A. Rossi,et al. Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses , 2011, British journal of haematology.
[9] W. D. Bidgood,et al. Introduction to the ACR-NEMA DICOM standard. , 1992, Radiographics : a review publication of the Radiological Society of North America, Inc.
[10] Lotty Hooft,et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. , 2006, Haematologica.
[11] P. Dupont,et al. Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.
[12] L. Mortelmans,et al. FDG-PET: procedure guidelines for tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[13] R. Buchert,et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] J. Paul,et al. The Internet and Clinical Trials: Background, Online Resources, Examples and Issues , 2005, Journal of medical Internet research.
[15] M. Heldmann,et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[17] Michel Meignan,et al. Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.
[18] T. Nihashi,et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Klaus Krippendorff,et al. Answering the Call for a Standard Reliability Measure for Coding Data , 2007 .
[20] J. Raemaekers,et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] B. Cheson,et al. Role of positron emission tomography in lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Levis,et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.
[23] G. Jerusalem,et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.
[24] Martin Hutchings,et al. PET/CT for Therapy Response Assessment in Lymphoma , 2009, Journal of Nuclear Medicine.
[25] P. Marsden,et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] Stephane Chauvie,et al. International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers , 2013, The Journal of Nuclear Medicine.
[27] D. Blockmans. (18F)FLUORO-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH FEVER OF UNKNOWN ORIGIN , 2004, Acta clinica Belgica.
[28] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.
[29] Alan Britten,et al. Routine quality control recommendations for nuclear medicine instrumentation , 2010, European Journal of Nuclear Medicine and Molecular Imaging.